Intratumoral Cancer Therapies Market

Intratumoral Cancer companies are Checkmate Pharmaceuticals, OncoSec Medical, Merck, Istari Oncology, Replimune/ Regeneron, Philogen, Sirnaomics, Nanobiotix.

ALBANY, NEW YORK, UNITED STATES, March 26, 2024 /EINPresswire.com/ -- DelveInsight's "Intratumoral Cancer Therapies Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Intratumoral Cancer Therapies, historical and forecasted epidemiology as well as the Intratumoral Cancer Therapies market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some facts of Intratumoral Cancer Therapies Market Report:
• In 2021, the total intratumoral cancer therapies market size was approximately USD 93 million which is expected to rise during the study period (2020–2034).
• As per DelveInsight's estimates, the total NMSC incident cases in the 7MM was 774,926 in 2020.
• Leading intratumoral cancer companies working in the market are Checkmate Pharmaceuticals, OncoSec Medical Incorporated, Merck, Istari Oncology, Replimune/ Regeneron, Philogen, Exicure, Sirnaomics, Nanobiotix, Intensity Therapeutics, NanOlogy, Lokon Pharma, Immunicum, DNAtrix, Treovir, Idera Pharmaceuticals, Immunovative Therapies, among other.
• At present, there are only three Intratumoral approved drugs namely Imlygic (Talimogene laherparepvec/T-VEC; Amgen), Hensify (NBTXR3; Nanobiotix) and Delytact (teserpaturev/G47; Daiichi Sankyo), Imlygic (Amgen) is the first and only FDA-approved viral therapy that is injected directly into melanoma tumors.
• The highest Intratumoral Cancer Therapies market share is primarily dominated by the USA in the 7MM that is anticipated to soar at a CAGR of 42% by 2030.

Download Intratumoral Cancer Therapies Market Snapshot report to understand which Intratumoral Cancer Therapy is going to nab the maximum market share @ Intratumoral Cancer Therapies Market Forecast

Intratumoral Cancer Therapies Overview
The cancer treatment landscape has transformed to incorporate novel therapies which mainly include chemotherapy, hormone therapy, immunotherapy, gene therapy, radiotherapy, stem cell transplant, surgery, and targeted therapy. However, there are patients who do not respond to any of the available treatment options or develop resistance to available therapies.

Intratumoral Cancer Therapies: Indication-wise Segmentation
DelveInsight's Intratumoral Cancer Therapies Market Insights Report offers historical as well as forecasted epidemiological analysis during the study period 2020-34 in the 7MM segmented into:
• Total Incident Cases of Selected Cancer Types (Melanoma, Nonmelanoma skin cancer, Head and Neck Cancer, Pancreatic Cancer, Renal Cell Carcinoma, Colorectal Cancer, Breast Cancer, Brain Cancer, and Soft Tissue Sarcoma)
• Target Patient Pool of Intratumoral Therapies by Cancer Types
• Treated Cases by Cancer Types

Understand how Intratumoral Cancer Therapeutics Landscape is going to shape by 2034 in 7 Major Markets by downloading @ Intratumoral Cancer Therapies Market Dynamics and Trends

Intratumoral Cancer Pipeline Therapies in Focus in the Report Analysis
• Vidutolimod (CMP-001): Checkmate Pharmaceuticals
• TAVO(tavokinogene telseplasmid): OncoSec Medical Incorporated
• CAVATAK (V937; CVA21): Merck & Co (Viralytics)
• PVSRIPO (PVS-RIPO): Istari Oncology
• RP1 (vusolimogene oderparepvec): Replimune/ Regeneron
• Daromun (Nidlegy): Philogen
• Cavrotolimod (AST-008): Exicure
• Cotsiranib (STP705): Sirnaomics
• Hensify (NBTXR3/ PEP503): Nanobiotix
• INT230-6 (Cisplatin/vinblastine): Intensity Therapeutics
• NanoPac (LSAM paclitaxel): NanOlogy
• Delolimogene mupadenorepvec (LOAd703): Lokon Pharma
• Intuvax (Ilixadencel): Immunicum
• Tasadenoturev (DNX-2401): DNAtrix
• G207: Treovir
• Tilsotolimod (IMO-2125): Idera Pharmaceuticals
• AlloStim: Immunovative Therapies

Learn more about available treatments @ Intratumoral Cancer Therapies and Drugs

Intratumoral Cancer Therapies Market Dynamics
DelveInsight's Intratumoral Cancer Therapies market analysis demonstrates that these therapies have immense potential to transform the treatment landscape by turning cold tumors into hot tumor and making their identification convenient by the immune system. However, the present understanding of Intratumoral therapies is poor and they also have faced backlash from the recent clinical trial failures at late stages; DelveInsight estimates that the future carries a promising outlook for the Intratumor Cancer Therapies market owing to potential emerging therapies, promising clinical trial results, the influx of pharma and biotech players, better R&D, and increasing healthcare expenditure.

Discover more about the future market share of the therapies @ https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Key Insights
2. Executive Summary of Intratumoral Cancer Therapies
3. Intratumoral Cancer Therapies Market Overview at a Glance
4. Competitive Intelligence Analysis for Intratumoral Cancer Therapies
5. Intratumoral Cancer Therapies Disease Background and Overview
6. Algorithm for Diagnosis of Intratumoral Cancer Therapies
7. Intratumoral Cancer Therapies Patient Journey
8. Intratumoral Cancer Therapies Epidemiology and Patient Population
9. Treatment Algorithm, Current Treatment, and Medical Practices
10. Intratumoral Cancer Therapies Epidemiology and Patient Population
11. Country Wise Epidemiology of Intratumoral Cancer Therapies
10. Intratumoral Cancer Therapies Treatment
12. Access and Reimbursement Overview of Intratumoral Cancer Therapies
13. Key Endpoints of Intratumoral Cancer Therapies Treatment
14. Intratumoral Cancer Therapies Emerging Therapies
15. Intratumoral Cancer Therapies: 7 Major Market Analysis
16. Intratumoral Cancer Therapies Market Unmet Needs
17. Intratumoral Cancer Therapies Market Drivers
18. Intratumoral Cancer Therapies Market Barriers
19. Attribute Analysis
20. KOL Reviews
21. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Ankit Nigam
DelveInsight Business Research
+1 469-945-7679
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
Instagram
YouTube

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.